Ketamine

ESO Publishes Peer-Reviewed Paper On Prehospital Ketamine Use At A National Level

Friday, June 11, 2021 - 1:13pm

The study uses data from the ESO Data Collaborative, one of the largest prehospital research databases in the country.

Key Points: 
  • The study uses data from the ESO Data Collaborative, one of the largest prehospital research databases in the country.
  • View the full release here: https://www.businesswire.com/news/home/20210611005060/en/
    The ketamine conversation has reached a national, mainstream audience, said Dr. Brent Myers, Chief Medical Officer for ESO.
  • EMS Ketamine Administrations: Based on data from the ESO Data Collaborative, EMS administered ketamine to 11,291 patients from January 1, 2019-December 31, 2019.
  • ESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data.

American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre

Wednesday, June 9, 2021 - 12:05pm

The Guidelines were developed and led by Braxia's CEO Dr. Roger S. McIntyre, M.D., and Braxia Health Medical Director, Joshua Rosenblat, M.D., M.

Key Points: 
  • The Guidelines were developed and led by Braxia's CEO Dr. Roger S. McIntyre, M.D., and Braxia Health Medical Director, Joshua Rosenblat, M.D., M.
  • Both Esketamine and intravenous (IV) Ketamine are the first glutamate-based treatments demonstrated to be rapidly effective in adults suffering from TRD.
  • "We have been encouraged to see increased availability and access to esketamine and ketamine for adults experiencing TRD.
  • We have been equally interested to assure that implementation of these rapid-acting treatments is conducted according to the best of science and clinical practice parameters," said Dr. Roger S. McIntyre, CEO, Braxia Scientific.

Leading Psychedelic Wellness Company Delic Signs Definitive Agreement to Acquire Ketamine Infusion Centers Llc, Bringing Physical Retail Chain to Delic Portfolio

Tuesday, June 8, 2021 - 1:30pm

VANCOUVER, BC, June 8, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has signed a definitive agreement (the "Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").

Key Points: 
  • VANCOUVER, BC, June 8, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has signed a definitive agreement (the "Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").
  • Supported by clinical trials and peer reviewed studies, ketamine infusions have emerged as a promising treatment option for chronic diseases and pain disorders.
  • We are focused on making psychedelic wellness truly accessible, and this is a huge development in the realization of that vision."
  • DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.

Ketamine One Enters Into Arrangement Agreement to Transfer Investments

Monday, June 7, 2021 - 11:00pm

In accordance with the terms of the Arrangement Agreement, the Company will transfer the investments and certain securities held by it (the "Transferred Assets") in exchange for 1,007,729 common shares of SpinCo (the "Consideration Shares").

Key Points: 
  • In accordance with the terms of the Arrangement Agreement, the Company will transfer the investments and certain securities held by it (the "Transferred Assets") in exchange for 1,007,729 common shares of SpinCo (the "Consideration Shares").
  • Subsequent to the transfer being completed, Ketamine One is expected to spin out the Consideration Shares (the "Spin-Out Shares") to the Companys shareholders.
  • It is anticipated that each Ketamine One shareholder will receive 1/110 of a Spin-Out Share for each Ketamine One common share held.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Ketamine One Launches Immersive Virtual Reality R&D Program at MindScape Clinic

Monday, June 7, 2021 - 11:00am

Clinic patients who select IVR-based treatments will receive a tailored therapy plan that includes a determination of their mental state and individual goals.

Key Points: 
  • Clinic patients who select IVR-based treatments will receive a tailored therapy plan that includes a determination of their mental state and individual goals.
  • With over 2,000 treatments administered since inception, MindScape also recently expanded its service offering to provide spa-like therapeutic treatment experiences.
  • Mindscape Ketamine & Infusions Therapy, PLLC is a clinic in Houston, Texas, offering affordable delivery of concierge IV ketamine therapy for treatment-resistant mood disorders, mental health disorders, and chronic pain conditions.
  • Mindscape Ketamine & Infusion Therapy, PLLC is the only IV ketamine clinic in Houston to offer virtual reality-based guided meditation to complement IV ketamine infusions in the treatment of depression, bipolar disorder, anxiety, PTSD, OCD, and other mood disorders.

Ketamine One Signs Definitive Agreement to Acquire Integrated Rehab and Performance Ltd.

Thursday, June 3, 2021 - 11:00am

Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.

Key Points: 
  • Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.
  • The IRP team is excited to join Ketamine One and combine resources to grow its clinics across Canada.
  • Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Ketamine (CAS 6740-88-1) Global Market Research Report 2021 - ResearchAndMarkets.com

Thursday, June 3, 2021 - 10:58am

The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Ketamine.
  • The fifth chapter deals with Ketamine market trends and forecast, distinguish Ketamine manufacturers and suppliers.
  • The Ketamine global market report key points:

Myconic Capital Becomes Ketamine One

Tuesday, June 1, 2021 - 11:00am

VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).

Key Points: 
  • VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).
  • Ketamine Ones board of directors has appointed Dr. Mark Kimmins as the Companys Chief Medical Officer.
  • We are excited to reveal the re-brand of the Company to Ketamine One, which more accurately reflects our vision to quickly become a leader in the delivery of breakthrough mental wellbeing treatments, said Adam Deffett, VP of Capital Markets for Ketamine One.
  • KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a single-purpose company focused becoming a North American leader in mental health.

Braxia Scientific Appoints Dr. David Greenberg to Board of Directors

Monday, May 31, 2021 - 12:01pm

TORONTO, May 31, 2021 /PRNewswire/ - Braxia Scientific Corp. (the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce it has appointed Dr. David Greenberg to its Board of Directors.

Key Points: 
  • TORONTO, May 31, 2021 /PRNewswire/ - Braxia Scientific Corp. (the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce it has appointed Dr. David Greenberg to its Board of Directors.
  • Dr. Greenberg consults for various companies on Sales, Marketing, Communications, and Business Development strategies.
  • Dr. Greenberg developed a national reputation for effectively conveying highly complex issues and concepts in a straightforward and entertaining manner.
  • Braxia Scientific is a research driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.

PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations

Thursday, May 27, 2021 - 1:00pm

(MediSynergics), a drug discovery company, to develop MediSynergics patented ketamine derivatives for pain and other CNS disorders and to investigate drug discovery and development of next-generation psychedelic derivatives, such as psilocybin, N,N-Dimethyltryptamine (DMT), 3,4-Methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD), mescaline, and ibogaine.

Key Points: 
  • (MediSynergics), a drug discovery company, to develop MediSynergics patented ketamine derivatives for pain and other CNS disorders and to investigate drug discovery and development of next-generation psychedelic derivatives, such as psilocybin, N,N-Dimethyltryptamine (DMT), 3,4-Methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD), mescaline, and ibogaine.
  • PharmaTher and MediSynergics will initially collaborate to advance the research of MediSynergics patented ketamine derivatives as an alternative to opioid medications for pain disorders using predictive preclinical animal models.
  • Efficacy of the patented ketamine derivatives were demonstrated to be comparable or better than ketamine when tested in a murine capsaicin inflammatory pain model.
  • Fabio Chianelli, Chief Executive Officer of PharmaTher, said, We are excited to work with MediSynergics in the discovery and development of novel psychedelic derivatives and formulations for pain and CNS disorders.